At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Astegolimab (drug)
- How long the study runs
- Study runs about 48 months (dates as stated)
- About the drug or intervention
- Astegolimab — drug: Participants will receive SC astegolimab Q2W
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Testing a treatment
- Ages
- 40 Years to 90 Years
- Who
- All
- Number of participants
- 2,000
- Started
- 2023-06-28
- Last checked
- 2026-08
Plain English Summary
What is this study?
- • Testing a new treatment for chronic obstructive pulmonary disease
- • Phase3 - 2,000 participants
- • The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmonary disease (COPD) who have completed the 52-week placebo-controlled treatment period in parent studies GB43311 or GB44332
Who can take part?
- • Ages 40 Years to 90 Years
- • Diagnosed with chronic obstructive pulmonary disease
Where?
- • Cambridge - Addenbrooke's Hospital
- • London - Guys Hospital
- • Bellshill - AES - DRS - Synexus Scotland Clinical Research Centre
- • Bradford - Bradford Royal Infirmary
- • +10 more UK sites
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmonary disease (COPD) who have completed the 52-week placebo-controlled treatment period in parent studies GB43311 or GB44332.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 40 Years - 90 Years
- Who can join: All genders
What the study is looking for
- ✓Completion of the 52-week treatment period in either parent GB43311 or GB44332
Who cannot take part
- ✗Withdrawal of consent and/or premature discontinuation from parent study
- ✗Any permanent discontinuation of the study treatment in parent study
- ✗Significant non-compliance in the parent study, specifically defined as missing scheduled visits, per investigator's...
- ✗Any new diagnosis of asthma according to the Global Initiative for Asthma guidelines or other accepted guidelines...
- ✗Any new unstable heart disease, myocardial infarction, or New York Heart Association Class III or IV heart failure...
See the full criteria
Where Is This Study? (14 UK sites)
Addenbrooke's Hospital
Cambridge CB2 0QQ, United Kingdom
Guys Hospital
London SE1 9RT, United Kingdom
AES - DRS - Synexus Scotland Clinical Research Centre
Bellshill ML4 3NJ, United Kingdom
Bradford Royal Infirmary
Bradford BD9 6RJ, United Kingdom
AES - DRS - Synexus Wales Clinical Research Centre
Cardiff CF15 9SS, United Kingdom
Royal Primary Care - Ashgate Manor
Chesterfield S40 4AA, United Kingdom
AES - DRS - NW Consortium Lancashire
Chorley PR7 7NA, United Kingdom
Castle Hill Hospital
Cottingham HU16 5JQ, United Kingdom
James Illingworth
hyp-tr.development.research@nhs.net01482 461883 or 461903AES - DRS - Synexus Midlands Clinical Research Centre
Edgbaston B15 2SQ, United Kingdom
AES - DRS - Synexus Hexham Clinical Research Centre
Hexham NE46 1QJ, United Kingdom
Glenfield Hospital
Leicester LE3 9QP, United Kingdom
AES - DRS - NW Consortium Merseyside
Liverpool L32 2AN, United Kingdom
Velocity Clinical Research North London - Percy Road - PPDS
London N12 8BU, United Kingdom
Queen Anne Street Medical Centre
London W1G 8HU, United Kingdom